title: Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.
abstract: OBJECTIVE
  To evaluate the impact of therapeutic education on adherence to antiviral treatment and sustained virological response (SVR) in a real-life setting in genotype 2/3 hepatitis C, as there are few adherence data in genotype 2/3 infection, even from randomized trials.
  
  
  METHODS
  This prospective survey included genotype 2/3 patients who received peg-interferon alfa-2b and ribavirin. There was no intervention. Adherence was self-reported over the past 4 wk (peg-interferon) or 7 d (ribavirin). Adherence to bitherapy was defined as adherence to the two drugs for >or= 20 wk. SVR was defined as undetectable RNA >or= 12 wk after the end of treatment.
  
  
  RESULTS
  370/674 patients received education during the first 3 mo of treatment. After 6 mo, adherence to bitherapy was higher in educated patients (61% vs 47%, P = 0.01). Adherence to peg-interferon was 78% vs 69% (P = 0.06). Adherence to ribavirin was 70% vs 56% (P = 0.006). The SVR (77% vs 70%, P = 0.05) and relapse (10% vs 16%, P = 0.09) rates tended to be improved. After adjustment for baseline differences, education improved adherence [Odds ratio (OR) 1.58, P = 0.04] but not the SVR (OR 1.54, P = 0.06).
  
  
  CONCLUSIONS
  In genotype 2/3 patients, therapeutic education helped maintain real-life adherence to bitherapy.
authors.affiliation: Department of Internal Medicine, Pitie-Salpetriere Hospital, 47-83 boulevard de l'Hopital, Paris cedex 13 F-75651, France. patrice.cacoub@psl.aphp.fr
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
authors.forename: Denis
authors.initials: D
authors.lastname: Ouzan
authors.forename: Pascal
authors.initials: P
authors.lastname: Melin
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Lang
authors.forename: Michel
authors.initials: M
authors.lastname: Rotily
authors.forename: Thierry
authors.initials: T
authors.lastname: Fontanges
authors.forename: Marina
authors.initials: M
authors.lastname: Varastet
authors.forename: Michel
authors.initials: M
authors.lastname: Chousterman
authors.forename: Patrick
authors.initials: P
authors.lastname: Marcellin
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005602:France; D005838:Genotype; D019538:Health Care Surveys; D007722:Health Knowledge, Attitudes, Practice; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D016017:Odds Ratio; D010353:Patient Education as Topic; D011092:Polyethylene Glycols; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b